Description: Invex Therapeutics Ltd Australia-based biopharmaceutical company that focuses on research and development of treatments for neurological conditions. The Company’s Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. It also focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its previously unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The Company intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimised to treat different neurological conditions.
Home Page: www.invextherapeutics.com
IXC Technical Analysis
38 Rowland Street
Perth,
WA
6008
Australia
Phone:
61 8 6382 0137
Officers
| Name | Title |
|---|---|
| Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB | CFO & Company Sec. |
| Prof. Alexandra Jean Sinclair | Exec. Director & Chief Scientific Officer |
| Dr. Thomas Duthy M.B.A., Ph.D. | Exec. Director |
| Ms. Carol Parish | Chief Operating Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4645 |
| Price-to-Sales TTM: | 237.1095 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |